PHOSPHODIESTERASE 9A AS MARKER OF MALIGNANT TUMOR OF PROSTATE GLAND Russian patent published in 2016 - IPC C12Q1/68 C12Q1/44 G01N33/574 

FIELD: biotechnology.

SUBSTANCE: methods and an immunoassay include following steps: determining phosphodiesterase 9A (PDE9A) level in sample; determining level of expression of reference gene in sample; normalisation of measured level of expression PDE9A relative to reference gene expression and comparing normalised level of expression with a predefined limit value selected so as to exclude hormone-sensitive prostate malignancy. Normalised expression level which is lower than limit value is indicative of malignant hormone-resistant prostate malignant tumour.

EFFECT: disclosed is a group of inventions related to PDE9A for use thereof as a marker of malignant prostate tumours and for use of PDE9A as a marker for diagnosis, detection, monitoring or prediction of prostate cancer or progression of malignant prostate tumour, and immunoassay.

8 cl, 15 dwg, 3 tbl, 3 ex